跳至主要内容
临床试验/NCT04954911
NCT04954911已完成不适用

Prospective, Multi-centre, Observational Registry to Evaluate the Clinical Performance of the Globe® Mapping and Ablation System for the Treatment of Atrial Fibrillation

Kardium Inc.2 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2021年11月2日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Kardium Inc.
入组人数
6
试验地点
2
主要终点
Freedom from AF at 12 months following ablation with the Globe System

研究概览

简要总结

This is an observational, multicentre, prospective, post-market product registry for participants with AF for whom ablation by the commercially available Globe Mapping and Ablation System was indicated before enrolment into the registry. The aim of the registry is to confirm the clinical performance and safety of the Globe Mapping and Ablation System in a real-life setting.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 18 years or older
  • Participants with a documented history of atrial fibrillation indicated for ablation using the Globe Mapping and Ablation System before enrolment into registry
  • Signed informed consent

排除标准

  • Contraindication for catheter ablation with the Globe System
  • Participant is currently participating in an investigational study that would interfere with registry endpoints according to the participating physician's discretion.
  • Physical or mental condition because of which, in the opinion of the physician, the participant is not able to give informed consent or comply with physician instructions.

结局指标

主要结局

Freedom from AF at 12 months following ablation with the Globe System

时间窗: Up to 1 year

Freedom from AF/AFL/AT at 12 months following ablation with the Globe System

时间窗: Up to 1 year

Device- and procedure-related adverse events within 12 months following ablation with the Globe System

时间窗: Up to 1 year

次要结局

未报告次要终点

研究者

发起方
Kardium Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Clinical Performance of the Globe® Mapping and... | 临床试验